IGF1 and glioblastoma: However, over 50% of GBM patients experience recurrence, which is driven by increased secretion of insulin-like growth factor-1 (IGF-1) from TAMs and IGF-1-induced activation of the phosphatidylinositol 3-kinase (PI3K) pathway in GBM cells [72].